DEZHAN HEALTHCARE(SZ:000813)2025-04-28 18:40Corporate Governance and Compliance - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[5] - The company has a structured governance framework with a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management[140] - The company is committed to maintaining compliance with laws and regulations regarding corporate governance and operations[141] - The company emphasizes the importance of protecting the rights of all shareholders, particularly minority shareholders, in its governance practices[139] - The company has established a market value management system to enhance its market value management practices[136] - The company has not reported any competitive conflicts with its controlling shareholder[144] - The company has a clear strategy for maintaining independence in business operations, personnel, assets, and finances[142] - The company has not implemented any employee stock ownership plans or other employee incentive measures during the reporting period[180] - The company has committed to ongoing monitoring and evaluation of risk control measures to ensure their effectiveness and compliance with established policies[183] - The company has conducted various research and communication activities with institutional investors to discuss operational conditions and R&D progress[134] Financial Performance - The company's operating revenue for 2024 was ¥466,485,016.50, a decrease of 6.34% compared to ¥498,088,171.28 in 2023[19] - The net profit attributable to shareholders for 2024 was -¥20,413,065.61, representing a decline of 124.50% from ¥83,314,246.81 in 2023[20] - The cash flow from operating activities for 2024 was -¥14,589,208.64, a significant drop of 111.41% compared to ¥127,872,780.78 in 2023[20] - The basic earnings per share for 2024 was -¥0.0095, down 124.87% from ¥0.0382 in 2023[20] - Total assets at the end of 2024 were ¥5,319,833,620.49, a decrease of 1.09% from ¥5,378,612,557.62 at the end of 2023[20] - The net assets attributable to shareholders at the end of 2024 were ¥5,158,023,472.59, down 1.53% from ¥5,237,902,679.94 at the end of 2023[20] - The company reported a negative net profit for the most recent accounting year, indicating uncertainty about its ability to continue as a going concern[21] - The company reported a net profit of -20,413,065.61 CNY for the fiscal year 2024, with an initial undistributed profit of 3,933,981,143.16 CNY[178] Research and Development - The company has a dedicated R&D platform with approximately 200 high-educated professionals, accounting for 20% of total employees, focusing on both technical improvements and new drug development[61] - R&D investment for 2024 reached CNY 78,203.1 million, a year-on-year increase of 53.05%, accounting for 16.76% of operating revenue, up 6.50 percentage points from the previous year[69] - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for new technology development[161] - The company has completed three pharmacodynamic studies and two mechanism studies for the CBD project aimed at treating pulmonary hypertension[88] - The company is developing a new drug for pancreatic cancer, having secured multiple patent rights across various countries[89] - The company is on track to launch a collagen product for post-surgical recovery by 2024, with ongoing trials for other cosmetic peptides[89] Market and Sales Performance - The total market size for lipid-regulating agents in China exceeded 20 billion yuan in 2023, with a year-on-year growth of 0.10%[30] - The retail market for oral lipid-regulating agents in China grew by 12.37% year-on-year in the first three quarters of 2024, with total sales exceeding 5 billion yuan[35] - The sales of atorvastatin calcium tablets reached 6.07 billion yuan in 2023, maintaining its position as the top product in the cardiovascular drug market[38] - The company is actively enhancing its OTC market presence and collaborating with strategic partners to promote "Alo" in retail markets[55] - The company is expanding its product matrix and exploring new market opportunities to drive growth and enhance its competitive position[56] Environmental Compliance - The company is compliant with multiple environmental protection laws and regulations, including the Environmental Protection Law and the Solid Waste Pollution Prevention Law[190] - The company holds a valid pollution discharge permit effective from June 12, 2024, to June 11, 2029[191] - The company has established emergency response plans for environmental incidents, with documentation filed with local authorities[192] - The company reported emissions of nitrogen oxides at 2 units with a concentration of 80 mg/Nm3, complying with the standard of 100 mg/Nm3[193] - The company has successfully completed environmental protection acceptance for its construction projects[192] Strategic Initiatives - The company is actively exploring new business areas, including biopolypeptides and medical services, with some segments already producing end products[43] - The company aims to reshape its competitiveness through a technology innovation strategy, focusing on biopharmaceuticals and expanding into the health industry[65] - The company plans to enhance shareholder returns through a three-year shareholder return plan (2023-2025) to balance interests between the company and its shareholders[177] - The company plans to use between 200 million and 300 million RMB of its own funds for share repurchases to enhance investor returns, with ongoing repurchase activities expected in 2025 based on market conditions[179] Risk Management - The company has identified and quantified risks in financial, investment, and compliance areas, establishing a comprehensive risk prevention mechanism to support stable development[182] - The company faces risks from market and policy changes, particularly due to the ongoing reforms in drug procurement and stricter regulations[132] - Rising production costs due to raw material prices and logistics are a concern, prompting the company to optimize supplier management and production technology[132] Employee Management - The total number of employees at the end of the reporting period was 1,054, with 435 in production, 179 in sales, and 202 in technical roles[171][172] - The company has established a three-dimensional dynamic compensation system focused on value creation and performance-driven principles[173] - The training plan for 2024 includes 24 different training programs, covering areas such as GMP regulations, financial management, and quality management systems[174][175]